Next-generation ADC treatments that will overcome the limitations and resistance of existing ADCs

Suven Pharmaceuticals acquires controlling stake in US-based NJ Bio

GSK multiple myeloma drug’s DREAMM comeback continues with phase 3 data at ASH

Merck’s investigational zilovertamab vedotin in combination with R-CHP demonstrates complete response rate of 100% at...

NextCure announces acceptance of IND application for LNCB74

Datopotamab deruxtecan granted breakthrough therapy designation in US for patients with previously treated advanced EGFR-mutated...

Blenrep (belantamab mafodotin) combination accepted for priority review in China in relapsed/refractory multiple myeloma